Pharma Equity Group A/S (CPH:PEG)

Pharma Equity Group Income Statement

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	12.29	11.81	5.78
Research & Development	9	8.82	5.5
Operating Expenses	21.29	25.03	11.28
Operating Income	-21.29	-25.03	-11.28
Interest Expense	-4.96	-1.56	-0.02
Interest & Investment Income	0.01	0.01	-
Currency Exchange Gain (Loss)	-0	-	-
Other Non Operating Income (Expenses)	-0	-	-
Pretax Income	-26.24	-26.58	-11.3
Income Tax Expense	-1.82	-2.23	-1.86
Net Income	-24.42	-24.35	-9.44
Net Income to Common	-24.42	-24.35	-9.44
Shares Outstanding (Basic)	1,068	1,080	954
Shares Outstanding (Diluted)	1,077	1,089	977
Shares Change (YoY)	-1.10%	11.38%	-
EPS (Basic)	-0.02	-0.02	-0.01
EPS (Diluted)	-0.02	-0.02	-0.01
Free Cash Flow	-22.86	-16.7	-8.3
Free Cash Flow Per Share	-0.02	-0.01	-0.01
EBITDA	-21.27	-25.01	-11.02
D&A For EBITDA	0.02	0.02	0.26
EBIT	-21.29	-25.03	-11.28

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.